550. Bamlanivimab and Casirivimab/Imdevimab Treatment Outcomes: Results from a Large Healthcare System’s Structured Implementation Experience

BACKGROUND: Neutralizing antibody therapies targeting SARS-CoV-2 have been released for emergency use authorization by the FDA. Little is published on their real-world experience. In this retrospective study we share the results of our early experience on patient outcomes from use of these neutraliz...

Descripción completa

Detalles Bibliográficos
Autores principales: Polk, Christopher, Jacobs, Anna, Sampson, Mindy, Leonard, Michael, Medaris, Leigh Ann, Branner, Christopher, Goel, Vineet, Davidson, Lisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643780/
http://dx.doi.org/10.1093/ofid/ofab466.749

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643780/
http://dx.doi.org/10.1093/ofid/ofab466.749

Ejemplares similares